Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Unichem

- PMLiVE

Teva to cut 7000 jobs, close 15 manufacturing sites

Missed second-quarter sales expectations prompt the cutbacks

- PMLiVE

NICE backs Teva’s Cinqaero for severe asthma

Ruling will allow it to compete with GSK's rival IL-5 inhibitor Nucala

- PMLiVE

FDA panel backs Avastin and Herceptin biosimilars

A decision from the US regulator is expected in September

AstraZeneca AZ

AZ on the slide again as CEO departure rumours bubble away

Soriot’s alleged departure makes investors nervous ahead of looming MYSTIC trial results

EU flag

EU starts investigation of Aspen’s cancer drug pricing

Amid reports of price increases of several hundred per cent

- PMLiVE

Teva drops laquinimod for most common form of MS after failed trial

CONCERTO study showed no disability progression improvements over placebo

- PMLiVE

Teva launches asthma social media campaign

Hopes awareness drive will improve inhaler use

- PMLiVE

FDA approves Teva’s Huntington’s disease drug at second attempt

Austedo will treat fatal degenerative disorder chorea

- PMLiVE

Mylan deal with Roche clears path to biosimilar Herceptin launch

Covers global markets with the exception of Japan, Brazil and Mexico

Teva launches online cancer portal My Day

Follows social listening project on gender differences in cancer discussions

- PMLiVE

FDA sets August review date for Teva’s movement disorder drug

Could be first approved treatment for tardive dyskinesia

- PMLiVE

GSK’s Witty ends on a high, but warns 2017 looking ‘uncertain’

Generic competition to big-selling Seretide/Advair in the US could accelerate sales decline

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links